Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Research & Development (2016 - 2025)

Historic Research & Development for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $22.4 million.

  • Amphastar Pharmaceuticals' Research & Development rose 605.87% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year increase of 588.13%. This contributed to the annual value of $73.9 million for FY2024, which is 23.46% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Research & Development stood at $22.4 million, which was up 605.87% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Research & Development ranged from a high of $22.8 million in Q2 2022 and a low of $10.8 million during Q3 2021
  • Over the past 5 years, Amphastar Pharmaceuticals' median Research & Development value was $18.1 million (recorded in 2021), while the average stood at $18.2 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Research & Development crashed by 3902.18% in 2021 and then surged by 7207.92% in 2022.
  • Amphastar Pharmaceuticals' Research & Development (Quarter) stood at $17.3 million in 2021, then dropped by 0.29% to $17.2 million in 2022, then grew by 18.47% to $20.4 million in 2023, then decreased by 11.15% to $18.1 million in 2024, then increased by 23.22% to $22.4 million in 2025.
  • Its last three reported values are $22.4 million in Q3 2025, $20.1 million for Q2 2025, and $20.1 million during Q1 2025.